Legal analysis: compliance top of the agenda for big pharma

Do you think big pharma suffers from a negative image, and if so, to what extent do you think this is as a result of the numerous high-profile legal cases involving its leading companies?

It is true that the big pharma’s reputation has taken a dip in recent years. Certainly, the high-profile fraud cases and huge fines imposed on big pharma have damaged the reputation of the industry in general, but it is too simplistic to say that this is the only reason that the standing of the industry has declined.

Click here to read the full article which featured via PharmaFile and was written by Gillian Johnson and Charlotte Tillett,  heads of life sciences at Stevens & Bolton LLP.  

Contact our experts for further advice

Charlotte Tillett

Search our site